BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 32702368)

  • 1. Early Screening of African Americans (45-50 Years Old) in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program.
    Levin TR; Jensen CD; Chawla NM; Sakoda LC; Lee JK; Zhao WK; Landau MA; Herm A; Eby E; Quesenberry CP; Corley DA
    Gastroenterology; 2020 Nov; 159(5):1695-1704.e1. PubMed ID: 32702368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race/Ethnicity and Adoption of a Population Health Management Approach to Colorectal Cancer Screening in a Community-Based Healthcare System.
    Mehta SJ; Jensen CD; Quinn VP; Schottinger JE; Zauber AG; Meester R; Laiyemo AO; Fedewa S; Goodman M; Fletcher RH; Levin TR; Corley DA; Doubeni CA
    J Gen Intern Med; 2016 Nov; 31(11):1323-1330. PubMed ID: 27412426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower Abnormal Fecal Immunochemical Test Cut-Off Values Improve Detection of Colorectal Cancer in System-Level Screens.
    Berry E; Miller S; Koch M; Balasubramanian B; Argenbright K; Gupta S
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):647-653. PubMed ID: 31085338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal Cancer Screening After Sequential Outreach Components in a Demographically Diverse Cohort.
    Podmore C; Selby K; Jensen CD; Zhao WK; Weiss NS; Levin TR; Schottinger J; Doubeni CA; Corley DA
    JAMA Netw Open; 2024 Apr; 7(4):e245295. PubMed ID: 38625704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening.
    Quintero E; Carrillo M; Gimeno-García AZ; Hernández-Guerra M; Nicolás-Pérez D; Alonso-Abreu I; Díez-Fuentes ML; Abraira V
    Gastroenterology; 2014 Nov; 147(5):1021-30.e1; quiz e16-7. PubMed ID: 25127679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of fecal immunochemical test outreach, colonoscopy outreach, and usual care for boosting colorectal cancer screening among the underserved: a randomized clinical trial.
    Gupta S; Halm EA; Rockey DC; Hammons M; Koch M; Carter E; Valdez L; Tong L; Ahn C; Kashner M; Argenbright K; Tiro J; Geng Z; Pruitt S; Skinner CS
    JAMA Intern Med; 2013 Oct; 173(18):1725-32. PubMed ID: 23921906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Risk-Scoring System Combined With a Fecal Immunochemical Test Is Effective in Screening High-Risk Subjects for Early Colonoscopy to Detect Advanced Colorectal Neoplasms.
    Chiu HM; Ching JY; Wu KC; Rerknimitr R; Li J; Wu DC; Goh KL; Matsuda T; Kim HS; Leong R; Yeoh KG; Chong VH; Sollano JD; Ahmed F; Menon J; Sung JJ;
    Gastroenterology; 2016 Mar; 150(3):617-625.e3. PubMed ID: 26627608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program.
    Wieten E; Schreuders EH; Nieuwenburg SA; Hansen BE; Lansdorp-Vogelaar I; Kuipers EJ; Bruno MJ; Spaander MC
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1771-1777. PubMed ID: 27567693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening.
    Grobbee EJ; van der Vlugt M; van Vuuren AJ; Stroobants AK; Mallant-Hent RC; Lansdorp-Vogelaar I; Bossuyt PMM; Kuipers EJ; Dekker E; Spaander MCW
    Clin Gastroenterol Hepatol; 2020 Mar; 18(3):667-675.e1. PubMed ID: 31419575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy comparison among high risk factors questionnaire and Asia-Pacific colorectal screening score and their combinations with fecal immunochemical test in screening advanced colorectal tumor].
    Zhu N; Huang YQ; Song YM; Zhang SZ; Zheng S; Yuan Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2022 Jul; 25(7):612-620. PubMed ID: 35844124
    [No Abstract]   [Full Text] [Related]  

  • 11. Yield of Colonoscopy After a Positive Result From a Fecal Immunochemical Test OC-Light.
    Alsayid M; Singh MH; Issaka R; Laleau V; Day L; Lee J; Allison J; Somsouk M
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1593-1597.e1. PubMed ID: 29660528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-adapted Variation in Screening Interval of Fecal Immunochemical Test May Improve its Participation and Colonoscopy Acceptance.
    Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Joo KR; Lee JI
    J Clin Gastroenterol; 2017 Oct; 51(9):825-830. PubMed ID: 27824639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colorectal Cancer Screening: Recommendations for Physicians and Patients From the U.S. Multi-Society Task Force on Colorectal Cancer.
    Rex DK; Boland CR; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Levin TR; Lieberman D; Robertson DJ
    Gastroenterology; 2017 Jul; 153(1):307-323. PubMed ID: 28600072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial.
    Singal AG; Gupta S; Skinner CS; Ahn C; Santini NO; Agrawal D; Mayorga CA; Murphy C; Tiro JA; McCallister K; Sanders JM; Bishop WP; Loewen AC; Halm EA
    JAMA; 2017 Sep; 318(9):806-815. PubMed ID: 28873161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study.
    Jensen CD; Corley DA; Quinn VP; Doubeni CA; Zauber AG; Lee JK; Zhao WK; Marks AR; Schottinger JE; Ghai NR; Lee AT; Contreras R; Klabunde CN; Quesenberry CP; Levin TR; Mysliwiec PA
    Ann Intern Med; 2016 Apr; 164(7):456-63. PubMed ID: 26811150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.
    Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with use and non-use of the Fecal Immunochemical Test (FIT) kit for Colorectal Cancer Screening in Response to a 2012 outreach screening program: a survey study.
    Gordon NP; Green BB
    BMC Public Health; 2015 Jun; 15():546. PubMed ID: 26062732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer.
    Rex DK; Boland CR; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Levin TR; Lieberman D; Robertson DJ
    Am J Gastroenterol; 2017 Jul; 112(7):1016-1030. PubMed ID: 28555630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of multitarget stool DNA testing in African American patients.
    Cooper GS; Markowitz SD; Chen Z; Tuck M; Willis JE; Berger BM; Brenner DE; Li L
    Cancer; 2018 Oct; 124(19):3876-3880. PubMed ID: 30193399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenoma Detection Rate in Asymptomatic Patients with Positive Fecal Immunochemical Tests.
    Kligman E; Li W; Eckert GJ; Kahi C
    Dig Dis Sci; 2018 May; 63(5):1167-1172. PubMed ID: 29468377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.